When should I repeat a urinalysis to confirm microscopic hematuria (11‑30 red blood cells per high‑power field) and occasional yeast in an asymptomatic patient, and what follow‑up schedule is recommended?

When to Repeat Urinalysis for Microscopic Hematuria

Repeat urinalysis 6 weeks after treating any identified benign cause (such as yeast infection), and if hematuria persists (≥3 RBCs/HPF), proceed immediately with risk-stratified urologic evaluation rather than further observation. 1, 2

Initial Confirmation Requirements

• Confirm true microscopic hematuria with ≥3 RBCs per high-power field on microscopic examination—dipstick alone has only 65-99% specificity and produces false positives from yeast, menstrual contamination, or other substances. 1, 3
• For your patient with 11-30 RBCs/HPF, this already exceeds the diagnostic threshold and represents intermediate-to-high grade hematuria that warrants evaluation. 1, 4
• The presence of occasional yeast suggests possible vulvovaginal candidiasis contaminating the specimen, but this does not explain the degree of hematuria present. 1

Timing of Repeat Urinalysis

If Treating a Benign Cause (e.g., yeast infection):

• Treat the yeast infection appropriately, then repeat urinalysis 6 weeks after treatment completion to determine if hematuria resolves. 2, 3
• If hematuria resolves completely after treating the infection, no further urologic workup is needed in low-risk patients. 2, 3
• If hematuria persists at 6 weeks, proceed immediately with complete urologic evaluation—do not continue to observe. 1, 2

If No Clear Benign Cause Identified:

• With 11-30 RBCs/HPF in an asymptomatic patient, do not delay evaluation waiting for spontaneous resolution. 1, 4
• The American Urological Association guidelines indicate that even a single properly collected specimen showing this degree of hematuria may justify full evaluation in patients with risk factors. 1

Risk Stratification Determines Next Steps

Your patient's specific risk category determines the urgency and extent of evaluation:

High-Risk Features (require immediate cystoscopy + CT urography): 1, 2

• Age ≥60 years (both men and women)
• Smoking history >30 pack-years
• >25 RBCs/HPF on microscopy
• Any history of gross hematuria
• Occupational exposure to benzenes or aromatic amines
• Irritative voiding symptoms without documented infection

Intermediate-Risk Features (cystoscopy + imaging via shared decision-making): 1, 2

• Women age 50-59 years or men age 40-59 years
• Smoking history 10-30 pack-years
• 11-25 RBCs/HPF (your patient falls here)

Low-Risk Features (may defer extensive imaging): 1, 2

• Women <50 years or men <40 years
• Never smoker or <10 pack-years
• 3-10 RBCs/HPF
• No additional risk factors

Complete Urologic Evaluation Components

If hematuria persists after treating benign causes, the evaluation includes:

• Multiphasic CT urography (unenhanced, nephrographic, and excretory phases) to detect renal cell carcinoma, transitional cell carcinoma, and urolithiasis. 1, 5, 3
• Flexible cystoscopy for all patients ≥40 years or those with high-risk features to visualize bladder mucosa, urethra, and ureteral orifices. 1, 3
• Serum creatinine to assess renal function. 1, 3
• Urine culture if not already obtained, to definitively exclude infection. 1, 2

Long-Term Surveillance if Initial Workup Negative

If complete evaluation is negative but hematuria persists:

• Repeat urinalysis at 6,12,24, and 36 months with blood pressure monitoring at each visit. 1, 2
• After two consecutive negative annual urinalyses, no further testing is necessary. 1
• Immediate re-evaluation is warranted if gross hematuria develops, significant increase in microscopic hematuria occurs, new urologic symptoms appear, or hypertension/proteinuria develops. 1, 2

Critical Pitfalls to Avoid

• Never attribute hematuria solely to yeast contamination without confirming resolution after treatment—the degree of hematuria (11-30 RBCs/HPF) is too significant to dismiss. 1
• Do not perform serial urinalyses hoping for spontaneous resolution in intermediate- or high-risk patients—this delays cancer diagnosis. 1, 4
• Do not defer evaluation due to asymptomatic presentation—up to 5% of patients with asymptomatic microscopic hematuria harbor urinary tract malignancy, with higher rates in specific risk groups. 3, 6
• Delays in diagnosis beyond 9 months are associated with worse cancer-specific survival in bladder cancer patients. 1